Completed PHASE3 INTERVENTIONAL 1-arm NCT00395018

Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection

Sponsor: Bristol-Myers Squibb

Conditions Hepatitis B, Chronic

Interventions entecavir

Updated 7 times since 2017 Last updated: Apr 30, 2012 Started: Apr 30, 2007 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00395018, this PHASE3 trial focuses on Hepatitis B, Chronic and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bologna, Italy , Buenos Aires, Argentina , Chicago, United States , Cincinnati, United States , Cleveland, United States , Clichy, France , Dallas, United States , Fortaleza, Brazil , Heidelberg, Australia and 16 more locations